ARISTOSPAN
LOE Approachingtriamcinolone hexacetonide
NDAINJECTIONINJECTABLE
Approved
Jul 1969
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
3
Data completeness
2/8 — Basic
Drug data last refreshed 14h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Aristospan (triamcinolone hexacetonide) is a long-acting injectable corticosteroid approved in 1969 for intra-articular and intralesional use. It is used to treat inflammatory and allergic conditions, particularly joint inflammation, soft tissue inflammation, and dermatologic conditions. The drug works by suppressing the immune response and reducing inflammation at the site of injection.
LOE Approaching
As a legacy product with LOE approaching, Aristospan brand teams are likely small and focused on lifecycle extension or managed decline strategies rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (3)
Study of Cingal® and Triamcinolone Hexacetonide for the Relief of Knee Osteoarthritis Pain
Started Sep 2020
231 enrolled
Osteoarthritis, Knee
Study of Cingal for the Relief of Knee Osteoarthritis Compared to Triamcinolone Hexacetonide at 39 Weeks Follow up
Started Dec 2017
526 enrolled
Knee Osteoarthritis
Study of Cingal™ for the Relief of Knee Osteoarthritis Compared to Triamcinolone Hexacetonide
Started May 2017
576 enrolled
Knee Osteoarthritis
Career Relevance
Aristospan offers limited career growth potential given its LOE-approaching status and minimal linked job postings. Roles on this product typically focus on maintaining market share, managing reimbursement challenges, and operational efficiency rather than innovation or expansion.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.